On August 13, ASYMCHEM fell 5.15% in regular trading, trading at HKD 119.5/share, with turnover of HKD 196 million.
On the news front, the company disclosed on August 12 that its wholly-owned subsidiary Shanghai Asymchem Biotech Development recorded a net loss of RMB 44 million for 2025, with current liabilities exceeding current assets by RMB 84 million and accumulated losses reaching RMB 426 million. The subsidiary generated revenue of RMB 470 million for the full year, with core business contributing RMB 442 million.
Meanwhile, multiple institutional holders including China Southern Asset Management, Norges Bank, and Schroders PLC have successively reduced their H-share positions in recent weeks. The stock had accumulated significant gains after its A-share hit the daily limit up on August 7 and H-share rose over 5% on August 11, driven by the CXO sector rally following strong mid-year results from WuXi AppTec. The combination of subsidiary loss disclosure and institutional profit-taking amplified short-term correction pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments